Controlled gene delivery can enhance therapeutic outcome for cancer immune therapy for melanoma

Current Gene Therapy

Volumn 15, Issue 1, 2015, Pages 32-43

  Shirley, Shawna A ^a   Lundberg, Cathryn G ^a   Li, Fanying ^a   Burcus, Niculina ^a   Heller, Richard ^a,b  

^a OLD DOMINION UNIVERSITY   (United States)

^b OLD DOMINION UNIVERSITY   (United States)

Author keywords

Cytokine; Electrotransfer; Gene therapy; Immunotherapy; Interleukin 12; Melanoma

Indexed keywords

CD11B ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 12; PERFORIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CELL SUSPENSION; CONTROLLED GENE DELIVERY; CONTROLLED STUDY; ELECTROPORATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL STUDY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENE TARGETING; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; LONG TERM SURVIVAL; MELANOMA; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; OVERALL SURVIVAL; PHENOTYPE; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT; TUMOR REGRESSION; TUMOR VOLUME; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; GENE THERAPY; GENE TRANSFER; GENETICS; METABOLISM; PLASMID; PROCEDURES;

ANIMALS; FEMALE; GENE EXPRESSION; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; INTERLEUKIN-12; MELANOMA; MICE; MICE, INBRED C57BL; PLASMIDS; TREATMENT OUTCOME;

EID: 84926349168     PISSN: 15665232     EISSN: 18755631     Source Type: Journal    
DOI: 10.2174/1566523214666141121111630     Document Type: Article

References (42)

1. [1] Neumann E, Schaefer-Ridder M, Wang Y, Hofschneider PH. Gene transfer into mouse lyoma cells by electroporation in high electric fields. EMBO J 1982; 1(7): 841-5.
2. [2] Heller LC, Heller R. In vivo electroporation for gene therapy. Hum Gene Ther 2006; 17(9): 890-7.
3. [3] Favard C, Dean DS, Rols MP. Electrotransfer as a non viral method of gene delivery. Curr Gene Ther 2007; 7(1): 67-77.
4. [4] Canatella PJ, Karr JF, Petros JA, Prausnitz MR. Quantitative study of electroporation-mediated molecular uptake and cell viability. Biophys J 2001; 80(2): 755-64.
5. [5] Gehl J, Mir LM. Determination of optimal parameters for in vivo gene transfer by electroporation, using a rapid in vivo test for cell permeabilization. Biochem Biophys Res Commun 1999; 261(2): 377-80.
6. [6] Wolf H, Rols MP, Boldt E, Neumann E, Teissie J. Control by pulse parameters of electric field-mediated gene transfer in mammalian cells. Biophys J 1994; 66(2 Pt 1): 524-31.
7. [7] Cemazar M, Sersa G, Wilson J, et al. Effective gene transfer to solid tumors using different nonviral gene delivery techniques: electroporation, liposomes, and integrin-targeted vector. Cancer Gene Ther 2002; 9(4): 399-406.
8. [8] Gilbert RA, Jaroszeski MJ, Heller R. Novel electrode designs for electrochemotherapy. Biochim Biophys Acta 1997; 1334(1): 9-14.
9. [9] Berard M, Tough DF. Qualitative differences between naive and memory T cells. Immunology 2002; 106(2): 127-38.
10. [10] Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 1995; 13: 251-76.
11. [11] Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003; 3(2): 133-46.
12. [12] Brunda MJ, Luistro L, Warrier RR, et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 1993; 178(4): 1223-30.
13. [13] Del Vecchio M, Bajetta E, Canova S, et al. Interleukin-12: biological properties and clinical application. Clin Cancer Res 2007; 13(16): 4677-85.
14. [14] Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 1995; 87(8): 581-6.
15. [15] Colombo MP, Trinchieri G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002; 13(2): 155-68.
16. [16] Gogas HJ, Kirkwood JM, Sondak VK. Chemotherapy for metastatic melanoma: time for a change? Cancer 2007; 109(3): 455-64.
17. [17] Riker AI, Jove R, Daud AI. Immunotherapy as part of a multidisciplinary approach to melanoma treatment. Front Biosci 2006; 11: 1-14.
18. [18] Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005; 23(10): 2346-57.
19. [19] Daud AI, DeConti RC, Andrews S, et al. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol 2008; 26(36): 5896-903.
20. [20] Lucas ML, Heller L, Coppola D, Heller R. IL-12 plasmid delivery by in vivo electroporation for the successful treatment of established subcutaneous B16.F10 melanoma. Mol Ther 2002; 5(6): 668-75.
21. [21] Lucas ML, Heller R. IL-12 gene therapy using an electrically mediated nonviral approach reduces metastatic growth of melanoma. DNA Cell Biol 2003; 22(12): 755-63.
22. [22] Ugen KE, Kutzler MA, Marrero B, et al. Regression of subcutaneous B16 melanoma tumors after intratumoral delivery of an IL-15-expressing plasmid followed by in vivo electroporation. Cancer Gene Ther 2006; 13(10): 969-74.
23. [23] Marrero B, Shirley S, Heller R. Delivery of Interleukin-15 to B16 Melanoma by Electroporation Leads to Tumor Regression and Long-term Survival. Technol Cancer Res Treat 2014; 13(6): 551-60.
24. [24] Jalah R, Rosati M, Ganneru B, et al. The p40 subunit of interleukin (IL)-12 promotes stabilization and export of the p35 subunit: implications for improved IL-12 cytokine production. J Biol Chem 2013; 288(9): 6763-76.
25. [25] Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 1989; 24(3): 148-54.
26. [26] Cemazar M, Golzio M, Sersa G, et al. Control by pulse parameters of DNA electrotransfer into solid tumors in mice. Gene Ther 2009; 16(5): 635-44.
27. [27] Swain SL, Croft M, Dubey C, et al. From naive to memory T cells. Immunol Rev 1996; 150: 143-67.
28. [28] Ericsson PO, Hedlund G, Hansson J, Dohlsten M, Sjogren HO. Tumor-selective cytolysis is executed exclusively by CD45R+ CTL whereas allo-specific cytotoxicity can be executed also by CD45RCTL. Cell Immunol 1990; 126(1): 69-79.
29. [29] Kotnik T, Mir LM, Flisar K, Puc M, Miklavcic D. Cell membrane electropermeabilization by symmetrical bipolar rectangular pulses. Part I. Increased efficiency of permeabilization. Bioelectrochemistry 2001; 54(1): 83-90.
30. [30] Sersa G, Cemazar M, Semrov D, Miklavcic D. Changing electrode orientation improves the efficacy of electrochemotherapy of solid tumors in mice. Bioelectroch Bioener 1996; 39(1): 61-6.
31. [31] Todorovic V, Kamensek U, Sersa G, Cemazar M. Changing electrode orientation, but not pulse polarity, increases the efficacy of gene electrotransfer to tumors in vivo. Bioelectrochemistry 2014; 100:119-27.
32. [32] Heller LC, Cruz YL, Ferraro B, Yang H, Heller R. Plasmid injection and application of electric pulses alter endogenous mRNA and protein expression in B16.F10 mouse melanomas. Cancer Gene Ther 2010; 17(12): 864-71.
33. [33] Heller LC, Coppola D. Electrically mediated delivery of vector plasmid DNA elicits an antitumor effect. Gene Ther 2002; 9(19): 1321-5.
34. [34] Peng B, Zhao Y, Xu L, Xu Y. Electric pulses applied prior to intramuscular DNA vaccination greatly improve the vaccine immunogenicity. Vaccine 2007; 25(11): 2064-73.
35. [35] Liu H, Huang G, Tang Q, et al. The immunogenicity and safety of vaccination with purified Vero cell rabies vaccine (PVRV) in China under a 2-1-1 regimen. Hum Vaccin 2011; 7(2): 220-4.
36. [36] Shen W, Waldschmidt M, Zhao X, Ratliff T, Krieg AM. Antitumor mechanisms of oligodeoxynucleotides with CpG and polyG motifs in murine prostate cancer cells: decrease of NF-kappaB and AP-1 binding activities and induction of apoptosis. Antisense Nucleic Acid Drug Dev 2002; 12(3): 155-64.
37. [37] Cavallo F, Di Carlo E, Butera M, et al. Immune events associated with the cure of established tumors and spontaneous metastases by local and systemic interleukin 12. Cancer Res 1999; 59(2): 414-21.
38. [38] Yu WG, Ogawa M, Mu J, et al. IL-12-induced tumor regression correlates with in situ activity of IFN-gamma produced by tumorinfiltrating cells and its secondary induction of anti-tumor pathways. J Leukoc Biol 1997; 62(4): 450-7.
39. [39] Yu WG, Yamamoto N, Takenaka H, et al. Molecular mechanisms underlying IFN-gamma-mediated tumor growth inhibition induced during tumor immunotherapy with rIL-12. Int Immunol 1996; 8(6): 855-65.
40. [40] Watkins SK, Li B, Richardson KS, et al. Rapid release of cytoplasmic IL-15 from tumor-associated macrophages is an initial and critical event in IL-12-initiated tumor regression. Eur J Immunol 2009; 39(8): 2126-35.
41. [41] Taylor HR, West SK, Mmbaga BB, et al. Hygiene factors and increased risk of trachoma in central Tanzania. Arch Ophthalmol 1989; 107(12): 1821-5.
42. [42] Li S, Xia X, Mellieon FM, Liu J, Steele S. Candidate genes associated with tumor regression mediated by intratumoral IL-12 electroporation gene therapy. Mol Ther 2004; 9(3): 347-54.